Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioScience Health Innovations (BHIC) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for BioScience Health Innovations (BHIC) over the last 3 years, with Q3 2025 value amounting to $433196.0.

  • BioScience Health Innovations' Cost of Revenue rose 19223.99% to $433196.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 41759.4%. This contributed to the annual value of $536078.0 for FY2024, which is 37361.73% up from last year.
  • As of Q3 2025, BioScience Health Innovations' Cost of Revenue stood at $433196.0, which was up 19223.99% from $682985.0 recorded in Q2 2025.
  • In the past 5 years, BioScience Health Innovations' Cost of Revenue ranged from a high of $682985.0 in Q2 2025 and a low of $4746.0 during Q1 2023
  • Its 3-year average for Cost of Revenue is $190579.3, with a median of $73794.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in BioScience Health Innovations' Cost of Revenue was 82552.92% (2025), while the steepest drop was 19223.99% (2025).
  • Over the past 3 years, BioScience Health Innovations' Cost of Revenue (Quarter) stood at $67117.0 in 2023, then skyrocketed by 304.09% to $271213.0 in 2024, then skyrocketed by 59.73% to $433196.0 in 2025.
  • Its last three reported values are $433196.0 in Q3 2025, $682985.0 for Q2 2025, and $330925.0 during Q1 2025.